term follow-up of a larger cohort of patients will be needed to ascertain the overall efficacy of this type of therapy. In this phase II trial, we used a double dose-intensive chemotherapy and stem cell rescue protocol to treat Keywords: lymphoma; breast cancer; dose-intensive chemotherapy; ABMT; double transplant breast cancer (BCA) patients or non-Hodgkin's lymphoma patients (NHL). The first cycle consisted of highdose melphalan followed by ABMT. The second cycle used a novel chemotherapy combination; thiotepa, etoHigh-dose chemotherapy (HDC) with autologous hematoposide, carboplatin and cyclophosphamide (TECC) folpoietic stem cell rescue is being increasingly used for the lowed by ABMT. We treated 12 patients in total, nine treatment of solid tumors or hematopoietic malignancies with BCA, three with NHL. All nine BCA patients were that do not respond to, or relapse after conventional chemotreated with the two cycle protocol. The three NHL therapy. 1,2 High-dose combination chemotherapy with autopatients were treated with the second cycle only. Bone logous bone marrow transplant (ABMT) has become marrow (BM, 1 patient), peripheral blood stem cells increasingly popular as an effective treatment of breast (PBSC, 10 patients) or both (1 patient) were reinfused cancer (BCA) and non-Hodgkin's lymphoma (NHL).
limiting toxicity is mucositis. The TECC combination was Ten females were enrolled and two males. Their median age was 45 years with a range of 32-56. Of the three used since thiotepa, cyclophosphamide, and carboplatin all have steep dose-response curves and etoposide is a good patients with disseminated NHL, one patient had a lowgrade NHL, and the other two intermediate-grade NHL. At positive biochemical modulator of the above alkylating agents. All of the agents had been tried singly and in combitransplant their disease status was one in a second complete remission, one in a third complete remission, and one in a nation with other agents with encouraging results, but never in combination with each other.
second partial remission. The nine breast cancer patients all had histologically confirmed metastatic breast cancer. In the treatment of advanced non-Hodgkin's lymphoma (NHL) escalated doses of chemotherapeutic agents proThey entered the study with the following disease characteristics at transplant; four patients with stable, non-produced encouraging results in the 1970s. Because of this success many groups began using high-dose chemotherapy gressive metastatic disease, three patients with local metastatic spread (chest wall or ipsilateral axilla), one patient followed by autologous bone marrow transplant. With further refinement of the PBSC rescues, many believed that with metastatic spread to bone only, and one patient with sensitive metastatic disease in complete remission after HDC would be able to salvage many patients who had relapsed after conventional chemotherapy. Before our study standard treatment with FAC. All had responded to prior standard-dose chemotherapy. Bone marrow invasion was it had been demonstrated that multi-drug, high-dose regimens, including the agents carboplatin, cyclophosphamide, not ruled out by bone marrow examination before treatment. and etoposide, were successful in treating lymphoma. Therefore we decided to treat three patients with relapsed Cardiopulmonary function was determined by MUGA scan and pulmonary function tests. All patients needed an non-Hodgkin's lymphoma with the dose-escalated combination of thiotepa, etoposide, carboplatin and cyclophosejection fraction у50% and a DLCo (diffusing capacity of carbon monoxide) у50% to enroll in the study. Hepatic phamide (TECC) followed by reinfusion of bone marrow, PBSC, or both.
and renal dysfunction were evaluated by analyzing blood chemistries. No patients were allowed into the study with a serum creatinine or a serum bilirubin greater than twice normal. Good performance status was evaluated using the
Patients and methods
Eastern Cooperative Oncology Group (ECOG) performance score, and all patients had scores р1. Patients with relapsed NHL or metastatic BCA were eligible for this study, provided that they had good cardioPeripheral blood stem cells (PBSC) were first mobilized and collected using cyclophosphamide (4 g/m 2 ). Delayed pulmonary function and no evidence of hepatic or renal dysfunction. In addition, good performance status was stimulation with G-CSF (5-10 g/kg/day) was started on day +5 following cyclophosphamide. The cells were colrequired. A total of 12 patients entered the trial (which continues to accrue). They all signed written informed consent.
lected on days 12-15 by high volume (20-30 l) continuous apheresis on a COBE SPECTRA cell separator (COBE, Three patients had refractory or recurrent NHL. Nine patients were enrolled with metastatic BCA. The clinical Lakewood, CO, USA) and processed and frozen according to standard methods. Bone marrow was harvested in steady characteristics of all patients are shown in Table 1. state and the buffy coat cells obtained with a COBE 2991. The cells were then frozen in 10% DMSO, 40% autologous plasma in a controlled rate freezer (Cryogenics, Bloom- cycle of the intensive chemotherapy followed by ABMT.
Low-grade stage 1
In the first arm, the BCA patients were first treated with unit for an average of less than 1 day and were then discharged home. The patients were followed closely in the infusion over 4 days, and thiotepa as a single 24 h continuwith the TECC regimen are summarized in Table 4 . One death occurred due to cardiac/pulmonary dysfunction in a ous infusion on day −6. These were followed by reinfusion with PBSCs 60-72 h after the chemotherapy was completed patient heavily treated with doxorubicin before inclusion in this study. Neutropenic fever was a universal finding and (the schema is shown in Table 2 ). The average concentration of nucleated cells infused ranged from 1.6 × 10 10 to documented infections were present in seven (58%) patients. Most of the documented infections were due to 14.9 × 10 10 per patient (Table 3 ). All the patients were treated with hematopoietic growth factors (G-CSF) by daily Staphylococcus epidermis. All fevers and/or infections were managed successfully with broad-spectrum antisubcutaneous injections (5 g/kg), starting on day +1.
In the second arm, the NHL patients were only treated biotics. No deaths or major morbidity were attributed to infectious causes. All patients had grade 3-4 mucositis, with the novel protocol (TECC), receiving carboplatin, cyclophosphamide, and etoposide by intermittent infusion using the oral mucositis index (OMI). They were placed on an oral care program, including peridex rinses and removal over 4 days, and thiotepa as a single 24 h continuous infusion on day −6. These were followed by reinfusion with of fibrin deposits by gentle exfoliation under local anesthesia (viscous lidocaine). All patients were placed on temautologous bone marrow in one patient, PBSCs in another patient, and both marrow and PBSCs in the third patient, porary parenteral nutrition and were slowly advanced back to a regular diet when their mucositis began to improve. 60-72 h after the chemotherapy was completed (the schema is shown in Table 2 ).
Several patients tested positive for herpes simplex virus 1 and were placed on acyclovir with successful resolution of lesions. Nine patients had mild diarrhea or loose stools, with no Results documented Clostridium difficile toxin, or other documented ova and parasites. Renal or urological toxicity was Hematological recovery was rapid (Table 3) ; the ANC rose to greater than 500/l on day +11 (with a range of +8 to uncommon. Two patients developed mild renal insufficiency (2 × baseline creatinine) which resolved spon-+ 20) and the platelet count to greater than 20 000/l on day +12 (with a range of +6 to +20). Toxicities associated Table 4 Toxicity-associated with TECC Table 3 Hematopoietic rescue and recovery patients, one patient expired during the study, and one patient relapsed and has since expired. All the others are in complete remission and the majority returned to their field of work within 6 months of discharge. Of the three patients with NHL, two are in complete remission (CR); one relapsed and is now in CR after treatment with local radiation and interferon alpha-2B (IFN).
Discussion
Most women diagnosed with breast cancer (BCA) have localized and regional disease. Only a small percentage presents with metastatic disease. Therefore, death caused by BCA is usually due to failure to control regional or tutions began to use adjuvant cytotoxic chemotherapy as standard treatment for most women with BCA and axillary nodal involvement. In addition, recent strategies have taneously with appropriate fluid management. No etiology other than prior platinum exposure was found. Several of employed high-dose chemotherapy with HSC rescue. Several studies [2] [3] [4] [5] suggested that the use of high-dose chemothe patients developed hypokalemia and hypophosphatemia. These conditions were followed daily and suptherapy with hematological rescue in metastatic BCA was associated with improvement in overall survival and displemented appropriately. We found that treatment with mesna and forced alkaline diuresis was effective in preease-free intervals. Antman et al 3 studied 62 women with metastatic BCA who responded to conventional-dose venting hemorrhagic cystitis.
Abdominal pain or discomfort was a universal finding chemotherapy induction. They were treated with a single high-dose intensification course of cyclophosphamide, thiand was attributed to intestinal mucositis in most. None of the patients had documented cholecystitis or cholelithiasis, otepa and carboplatin (CTCb) with autologous marrow or peripheral stem-cell support. The overall median survival however some did have gallbladder 'sludge' on sonographic examination. None of the patients had clinically duration was 29 months for ABMT. Another recent randomized study compared HDC with standard-dose for significant bleeding, hepatic dysfunction, abscess formation, intestinal perforation, or veno-occlusive disease metastatic breast cancer with similar results. 6 Based on these promising results a double-intensification feasibility (VOD).
All of the surviving patients were discharged home in trial was designed for women with metastatic BCA. 7 Melphalan (140 to 180 mg/m 2 ) followed by G-CSF-mobilized stable condition, afebrile, with an absolute neutrophil count у500, and on trimethoprim/sulfamethoxazole for Pneumoperipheral blood progenitor cells, was used as the first BMT followed by CTCb, with marrow and PBSC support. cystis carinii pneumonia prophylaxis. Most patients received only anti-emetics and vitamins as discharge medi-
The progression-free survival rate at 15 months was 52 Ϯ 15.7%. cations. Discharge instructions were explicit and given to the patients and their families in discharge conferences.
Tandem transplants have been used by several investigators for the treatment of metastatic breast cancer.
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The Kaplan-Meyer estimates for overall survival are 83.3% at a mean of 37 months and for event-free survival Regimens have included sequential HDC with the abovementioned high-dose melphalan followed by CTCb, 7 highare 75% for all patients (Figures 1 and 2) . Of the nine BCA dose cyclophosphamide and thiotepa followed by melphalan, 8 with double CVP, 9 with a double CCV regimen, 10 or sequential transplants using CCV followed by busulfan and etoposide. 11 The two cycles, as in our study, are reasonably well tolerated, but the benefit from this type of approach remains to be demonstrated in comparison with single HDC with HSC rescue. A recent article by Ayash et al 12 concluded that double-dose intensification did not result in superior progression-free survivals when compared to single intensification with CTCb. We used a similar regimen including melphalan followed by CTCb, but used higher doses of the alkylating agents and added etoposide. Whether the modifications to the chemotherapy regimens are sufficient to justify the differences in outcomes between these two studies remains to be seen.
Several clinical trials have also shown consistently posi- intervals in patients with Hodgkin's disease and NHL treated with escalating doses of chemotherapeutic agents. to 14.9 × 10 10 cells per patient). A number of side-effects were observed with infusion of thawed autologous periphUsually the regimen includes an alkylating agent combined with antimetabolites, carboplatin or nitrosoureas. [13] [14] [15] [16] More eral stem cells. These included transient, usually self-limited hemoglobinuria, nausea, abdominal cramps, diarrhea, recently, Schenkein et al 17 were able to demonstrate the safety and effectiveness of a multi-drug high-dose regimen chills, dyspnea, hypertension and bradycardia. In spite of receiving a high cell dose, our patients tolerated the consisting of cyclophosphamide 7200 mg/m 2 , carboplatin 1600 mg/m 2 and etoposide 1600 mg/m 2 (CCV) followed infusion quite well, without major toxicity. In summary, this phase II trial indicates that this novel by ABMT in 32 patients with lymphoma.
Although there are studies that do not support a role for chemotherapy regimen can achieve high rates of remission and progression-free survival with reliable and stable long-HDC in NHL, 18 the recent results from the Parma study argue strongly in favor of a role for HDC with stem cell term trilinear hematopoietic engraftment without causing unmanageable toxicities. These results are encouraging and rescue in relapsed NHL.
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In our study, patients were treated with high-dose mellong-term follow-up of a larger cohort of patients is needed to ascertain the overall efficacy of this type of therapy. phalan in the first cycle, as many others have done, and then we used our novel protocol in the second cycle. ThioMore investigation needs to be done, obviously, to further clarify these issues and to improve the survival rates of tepa was originally included because of its potential for dose escalation with hematopoietic support. 20 However, these two common malignancies. because in a prior pilot study severe mucositis was associated with dose escalated thiotepa (up to 600 mg/m 2 ), we decided not to escalate beyond 300 mg/ We also evaluated the role of hematopoietic stimulating In our study we used a high number of PBSCs (1.6 × 10
